1 |
Weaver DA, Crawford EL, Warner KA, et al (2005). ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines. Mol Cancer, 4, 18.
DOI
ScienceOn
|
2 |
Wohrer SS, Raderer M, Hejna M (2004). Palliative chemotherapy for advanced gastric cancer. Ann Oncol, 15, 1585-95.
DOI
ScienceOn
|
3 |
Wu X, Gu J, Wu TT, et al (2006). Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol, 24, 3789-98.
DOI
ScienceOn
|
4 |
Yoon AJ, Kuo WH, Lin CW, et al (2011). Role of ERCC5 polymorphism in risk of hepatocellular carcinoma. Oncol Lett, 2, 911-4.
|
5 |
de las Penas R, Sanchez-Ronco M, Alberola V, et al (2006). Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol, 17, 668-75.
DOI
ScienceOn
|
6 |
Gurubhagavatula S, Liu G, Park S, et al (2004). XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol, 22, 2594-601.
DOI
ScienceOn
|
7 |
He J, Qiu LX, Wang MY, et al (2012). Polymorphisms in the XPG gene and risk of gastric cancer in Chinese populations. Hum Genet, 131, 1235-44.
DOI
ScienceOn
|
8 |
Ichikawa W (2006). Prediction of clinical outcome of fluoropyrimidine-based chemotherapy for gastric cancer patients, in terms of the 5-fluorouracil metabolic pathway. Gastric Cancer, 9, 145-55.
DOI
ScienceOn
|
9 |
International Agency for Research on Cancer (2008). Globocan 2008: Stomach Cancer incidence, Mortality and Prevalence Worldwide in 2008. IARC.
|
10 |
Isla D, Sarries C, Rosell R, et al (2004). Single nucleotide polymorphisms and outcome in docetaxel-cisplatintreated advanced non-small-cell lung cancer. Ann Oncol, 15, 1194-203.
DOI
ScienceOn
|
11 |
Keam B, Im SA, Han SW, et al (2008). Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms polymorphisms as a predictive and prognostic marker. BMC Cancer, 8, 148.
DOI
|
12 |
Kiyohara C, Yoshimasu K (2007). Genetic polymorphisms in the nucleotide excision repair pathway and lung cancer risk: a meta-analysis. Int J Med Sci, 4, 59-71.
|
13 |
Liu YP, Ling Y, Zhang YP, et al (2011). Predictive values of platinum-related gene polymorphisms in gastric cancer patients on oxaliplatin-based adjuvant chemotherapy. Zhonghua Yi Xue Za Zhi, 91, 256-9.
|
14 |
Ma H, Yu H, Liu Z, et al (2012). Polymorphisms of XPG/ERCC5 and risk of squamous cell carcinoma of the head and neck. Pharmacogenet Genomics, 22, 50-7.
DOI
ScienceOn
|
15 |
Monzo M, Moreno I, Navarro A, et al (2007). Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fl uoropyrimidine.Oncology, 72, 364-70.
DOI
ScienceOn
|
16 |
Parkin DM (2001). Global cancer statistics in the year 2000. Lancet Oncol, 2, 533-43.
DOI
ScienceOn
|
17 |
Quintela-Fandino M, Hitt R, Medina PP, et al (2006). DNA repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatinbased induction chemotherapy. J Clin Oncol, 24, 4333-9.
DOI
ScienceOn
|
18 |
Ruzzo A, Graziano F, Kawakami K, et al (2006). Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. J Clin Oncol, 24, 1883-91.
DOI
ScienceOn
|
19 |
Bewick MA, Conlon MS, Lafrenie RM (2006). Polymorphisms in XRCC1, XRCC3, and CCND1 and survival after treatment for metastatic breast cancer. J Clin Oncol, 24, 5645-51.
DOI
ScienceOn
|
20 |
Saldivar JS, Lu KH, Liang D, et al (2007). Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients. Gynecol Oncol, 107, 223-9.
DOI
ScienceOn
|